Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT Versus Oral Melphalan and High-Dose Dexamethasone in AL Amyloidosis
NCT00344526Phase 3Completed
- Sponsor
- CHU de Limoges
- Start
- Jan 2000
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of melphalan, dexamethasone in primary systemic amyloidosis, sponsored by CHU de Limoges. Started Jan 2000; status: completed.
02
Drugs
melphalandexamethasone
03
Conditions
primary systemic amyloidosis
Beyond the preview
Go deeper on NCT00344526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00344526.